Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 1.00 |
| ▸ | GNA15 | P30679 | 1/20 | 0.63 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.63 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924433 | 1.00 | FFAR1 (1.00) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL11804605 | 0.84 | FFAR1 (0.71) | FFAR1FFAR4PTGS1HIF1A | |
| Propionic Acid SCHEMBL2305821 | 0.81 | FFAR1 (0.74) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL4748821 | 0.81 | FFAR1 (0.74) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL5180058 | 0.80 | FFAR1 (0.66) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL14924230 | 0.78 | FFAR1 (0.82) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL2305825 | 0.78 | FFAR1 (0.68) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL5859386 | 0.78 | FFAR1 (0.64) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| Gw9508 SCHEMBL29766936 | 0.78 | FFAR1 (1.00) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| Gw9508 SCHEMBL364468 | 0.78 | FFAR1 (1.00) | FFAR1GNA15PTGER3FFAR4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106998743-B | Compounds for modulating fatty acid receptor activity and pet food comprising the same | 马斯公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-106715409-B | Complex preparation for preventing or treating metabolic diseases comprising 3- (4- (benzyloxy) phenyl) -4-hexynoic acid derivative and other active ingredients | 现代药品株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111423408-A | Compound preparation for preventing or treating metabolic diseases | 现代药品株式会社 | 2020-07-17 | — | — | CN | disclosed |
| EP-2987791-B1 | 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, SUITABLE FOR PREVENTING AND TREATING METABOLIC DISEASES | HYUNDAI PHARM CO LTD (KR) | 2019-07-17 | — | — | EP | disclosed |
| US-9969723-B2 | 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient | HYUNDAI PHARM CO., LTD (KR) | 2018-05-15 | — | — | US | disclosed |
| CN-105121423-B | 3- (4- (benzyloxy) phenyl) hex-4-ynoic acid derivative, method for preparing the same, and pharmaceutical composition for preventing and treating metabolic diseases comprising the same as an effective ingredient | 现代药品株式会社 | 2017-06-09 | — | — | CN | disclosed |
| CN-106715409-A | Complex preparation for preventing or treating metabolic diseases comprising novel 3- (4- (benzyloxy) phenyl) -4-hexenoic acid derivative and other active ingredients | 现代药品株式会社 | 2017-05-24 | — | — | CN | disclosed |
| EP-2987791-A1 | NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | HYUNDAI PHARM CO., LTD (KR) | 2016-01-28 | — | — | US | disclosed |
| CN-103980235-A | GPR120 receptor agonists and uses thereof | CYMABAY THERAPEUTICS INC | 2014-08-13 | — | — | CN | disclosed |
| CN-102307860-B | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2014-07-02 | — | — | CN | disclosed |
| CN-102307860-A | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2012-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | GPR119, INSR, IRS1 | FFAR1 5/4885GNA15 1255/4885PTGER3 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.